Tech Company Inital Public Offerings
Acumen Pharmaceuticals IPO
Acumen Pharmaceuticals, operating out of Charlottesville, had an IPO event on 7/6/2021.
Transaction Overview
Company Name
Announced On
7/6/2021
Transaction Type
IPO
Amount
$160,000,000
Proceeds Purpose
The company will allocate the IPO proceeds as follows: approximately $75.0 million to fund the completion of our ongoing Phase 1 clinical trial of ACU193 and, subject to the successful completion of that trial, the Phase 2 portion of a future Phase 2/3 adaptive trial of ACU193; approximately $30.0 million to fund chemistry, manufacturing and other research and development activities; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
427 Park St.
Charlottesville, VA 22902
USA
Charlottesville, VA 22902
USA
Phone
Website
Email Address
Overview
Acumen Pharmaceuticals is focused on discovering and developing best in class therapeutics and diagnostics for Alzheimers disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel O'Connell
Chief Medical Officer
Eric Siemers
VP - Regulatory Affairs
Janice Hitchcock
Browse more venture capital transactions:
Prev: 7/5/2021: Physna venture capital transaction
Next: 7/7/2021: Wagmo venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs